J&J nabs Pharmacyclics cancer candidate in $975M deal

Johnson & Johnson's ($JNJ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are met--for a midstage blood-cancer treatment. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.